Joseph Lewnard

Dr. Joseph Lewnard


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
JLJoseph Lewnard
Joseph Lewnard
NLNathan C Lo
Nathan C Lo

6 November 2020 in Science
Verified
Journal Article
Open access
PDF file
RLRamanan Laxminarayan
Ramanan Laxminarayan
BWBrian Wahl
Brian Wahl
SDShankar Reddy Dudala
Shankar Reddy Dudala
KGK. Gopal
K. Gopal
CBChandra Mohan B
Chandra Mohan B
JLJoseph Lewnard
Joseph Lewnard
Epidemiology in southern India: By August 2020, India had reported several million cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with cases tending to show a younger age distribution than has been reported in higher-income countries. Laxminarayan et al. analyzed data from the Indian states of Tamil Nadu and Andhra Pradesh, which have developed rigorous contact tracing and testing systems (see the Perspective by John and Kang). Superspreading predominated, with 5% of infected individuals accounting for 80% of cases. Enhanced transmission risk was apparent among children and young adults, who accounted for one-third of cases. Deaths were concentrated in 50- to 64-year-olds. Incidence did not change in older age groups, possibly because of effective stay-at-home orders and social welfare programs or socioeconomic status. As in other settings, however, mortality rates were associated with older age, comorbidities, and being male. Science , this issue p. 691 ; see also p. 663

8 June 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JLJoseph Lewnard
Joseph Lewnard
VHVennis X. Hong
Vennis X. Hong
MPManish M. Patel
Manish M. Patel
RKRebecca Kahn
Rebecca Kahn
MLMarc Lipsitch
Marc Lipsitch
STSara Tartof
Sara Tartof

23 May 2024 in The Lancet
Verified
Journal Article
Closed access
JLJoseph Lewnard
Joseph Lewnard
ECEsmita Charani
Esmita Charani
AGAlec Gleason
Alec Gleason
LHLi Yang Hsu
Li Yang Hsu
WKWasif Ali Khan
Wasif Ali Khan
RLRamanan Laxminarayan
Ramanan Laxminarayan

21 May 2018 in Vaccines
Verified
Journal Article
Open access
PDF file
JLJoseph Lewnard
Joseph Lewnard
SCSarah Cobey
Sarah Cobey
The imperfect effectiveness of seasonal influenza vaccines is often blamed on antigenic mismatch, but even when the match appears good, effectiveness can be surprisingly low. Seasonal influenza vaccines also stand out for their variable effectiveness by age group from year to year and by recent vaccination status. These patterns suggest a role for immune history in influenza vaccine effectiveness, but inference is complicated by uncertainty about the contributions of bias to the estimates themselves. In this review, we describe unexpected patterns in the effectiveness of seasonal influenza vaccination and explain how these patterns might arise as consequences of study design, the dynamics of immune memory, or both. Resolving this uncertainty could lead to improvements in vaccination strategy, including the use of universal vaccines in experienced populations, and the evaluation of vaccine efficacy against influenza and other antigenically variable pathogens.

22 May 2020 in BMJ
Verified
Journal Article
Open access
PDF file
JLJoseph Lewnard
Joseph Lewnard
VLVincent X Liu
Vincent X Liu
MJMichael L Jackson
Michael L Jackson
MSMark A Schmidt
Mark A Schmidt
BJBritta L Jewell
Britta L Jewell
JBJim Bellows
Jim Bellows
Objective: To understand the epidemiology and burden of severe coronavirus disease 2019 (covid-19) during the first epidemic wave on the west coast of the United States.Design: Prospective cohort study.Setting: Kaiser Permanente integrated healthcare delivery systems serving populations in northern California, southern California, and Washington state.Participants: 1840 people with a first acute hospital admission for confirmed covid-19 by 22 April 2020, among 9 596 321 healthcare plan enrollees. Analyses of hospital length of stay and clinical outcomes included 1328 people admitted by 9 April 2020 (534 in northern California, 711 in southern California, and 83 in Washington).Main outcome measures: Cumulative incidence of first acute hospital admission for confirmed covid-19, and subsequent probabilities of admission to an intensive care unit (ICU) and mortality, as well as duration of hospital stay and ICU stay. The effective reproduction number (RE) describing transmission dynamics was estimated for each region.Results: As of 22 April 2020, cumulative incidences of a first acute hospital admission for covid-19 were 15.6 per 100 000 cohort members in northern California, 23.3 per 100 000 in southern California, and 14.7 per 100 000 in Washington. Accounting for censoring of incomplete hospital stays among those admitted by 9 April 2020, the estimated median duration of stay among survivors was 9.3 days (with 95% staying 0.8 to 32.9 days) and among non-survivors was 12.7 days (1.6 to 37.7 days). The censoring adjusted probability of ICU admission for male patients was 48.5% (95% confidence interval 41.8% to 56.3%) and for female patients was 32.0% (26.6% to 38.4%). For patients requiring critical care, the median duration of ICU stay was 10.6 days (with 95% staying 1.3 to 30.8 days). The censoring adjusted case fatality ratio was 23.5% (95% confidence interval 19.6% to 28.2%) among male inpatients and 14.9% (11.8% to 18.6%) among female inpatients; mortality risk increased with age for both male and female patients. Reductions in RE were identified over the study period within each region.Conclusions: Among residents of California and Washington state enrolled in Kaiser Permanente healthcare plans who were admitted to hospital with covid-19, the probabilities of ICU admission, of long hospital stay, and of mortality were identified to be high. Incidence rates of new hospital admissions have stabilized or declined in conjunction with implementation of social distancing interventions.